CAPTRUST Financial Advisors’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$91K Buy
15,275
+2,207
+17% +$10.5K ﹤0.01% 3161
2026
Q2
$57.9K Sell
13,068
-3,366
-20% -$14.4K ﹤0.01% 3120
2026
Q1
$71.8K Buy
16,434
+2,387
+17% +$11.3K ﹤0.01% 2855
2025
Q4
$70.9K Sell
14,047
-1,231
-8% -$5.72K ﹤0.01% 2645
2025
Q3
$53K Buy
15,278
+2,574
+20% +$9.7K ﹤0.01% 2557
2025
Q2
$43.2K Buy
+12,704
New +$42.3K ﹤0.01% 2439
2022
Q3
– Sell
-338
Closed -$4K – 2495
2022
Q2
$4K Sell
338
-26
-7% -$259 ﹤0.01% 4171
2022
Q1
$4K Buy
+364
New +$4.92K ﹤0.01% 4237

Other funds holding CTKB

CAPTRUST Financial Advisors's CTKB Position: Q3 2026 in Review

CAPTRUST Financial Advisors increased its Cytek Biosciences (CTKB) stake by 17% in Q3 2026, buying an estimated $10.5K and bringing the position to 15,275 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #3161.

CAPTRUST Financial Advisors first reported a position in CTKB in Q1 2022 and has held it in 8 quarters since. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • CAPTRUST Financial Advisors held 15,275 shares of Cytek Biosciences worth $91K as of Q3 2026.
  • CAPTRUST Financial Advisors bought 2,207 Cytek Biosciences shares in Q3 2026, an estimated $10.5K.
  • Cytek Biosciences made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3161 holding.
  • CAPTRUST Financial Advisors first reported a position in Cytek Biosciences in Q1 2022 and has held it in 8 quarters since.
  • 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.